Caris Life Sciences had its Relative Strength (RS) Rating upgraded from 73 to 86 Wednesday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique RS Rating tracks technical performance by showing how a stock's price movement over the last 52 weeks measures up against that of other stocks on the major indexes.
Decades of market research reveals that the best-performing stocks often have an RS Rating of at least 80 as they begin their biggest climbs.
Caris Life Sciences has moved more than 5% past a 30.70 entry in a first-stage ipo base, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Caris Life Sciences showed 0% EPS growth in the latest quarterly report. Sales rose 81%.
The company holds the No. 8 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings, IQVIA Holdings and Centessa Pharma ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
